APRIL WASHINGTON: Open Payments
NPI 1104441039 · MOULTRIE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$814 in 42 payments from 10 companies in 2025. Trend: 2023 $709 · 2024 $368 · 2025 $814
Food & beverage: $814
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 9 | $193 |
| Vanda Pharmaceuticals Inc. | 11 | $172 |
| Alkermes, Inc. | 5 | $99 |
| Teva Pharmaceuticals USA, Inc. | 5 | $96 |
| ABBVIE INC. | 4 | $83 |
| Neurocrine BioSciences, Inc. | 3 | $77 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
Products named: COBENFY, FANAPT, VRAYLAR, INGREZZA, UZEDY, ARISTADA, REXULTI, LYBALVI.
Industry payments across GA — which companies pay providers there.
